Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis

BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis. The objective of this study was to systematically assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Fangyuan, Chen, Zhaoyan, Xu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Meta-Analysis and Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567701/
https://www.ncbi.nlm.nih.gov/pubmed/31096817
http://dx.doi.org/10.1177/0300060519847414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567701/
https://www.ncbi.nlm.nih.gov/pubmed/31096817
http://dx.doi.org/10.1177/0300060519847414

Ejemplares similares